Maintenance after GLP-1 weight loss: what studies show after treatment stops.

Start with the boundary

This guide reviews group-level evidence about weight maintenance after trial treatment was withdrawn. It does not tell anyone to start, continue, stop, restart, taper, switch, or change a dose of a GLP-1 or related medicine.

The evidence applies to named products, defined trial populations, and measured follow-up periods. It is not a personal forecast, and findings from approved branded products should not be transferred to compounded, unapproved, or research-use products.

What the STEP 1 extension can show

The STEP 1 extension was an exploratory follow-up of a 327-participant exploratory extension subset of adults with overweight or obesity and without diabetes. Semaglutide 2.4 mg and the trial lifestyle intervention ended at week 68; the extension observed participants off treatment from week 68 to week 120.

In the prior semaglutide group, mean weight loss was 17.3% at week 68. By week 120, participants had regained a mean 11.6 percentage points, leaving a mean 5.6% reduction from the original baseline. These averages describe the extension subset, not what any one person will regain.

What SURMOUNT-4 can show

SURMOUNT-4 used a different randomized-withdrawal design. After a 36-week open-label tirzepatide lead-in, 670 randomized participants without diabetes either continued tirzepatide or switched to placebo for 52 weeks, through week 88.

From randomization to week 88, mean weight changed by -5.5% in the continuation group and +14.0% in the placebo-switch group. At week 88, 89.5% of the continuation group and 16.6% of the placebo-switch group had maintained at least 80% of the lead-in weight reduction. This trial comparison does not prescribe what a reader should do or establish outcomes beyond its selected population and timeframe.

What the broader discontinuation review adds

A 2025 systematic review and meta-analysis combined randomized anti-obesity-medication trials that treated participants for at least four weeks and followed them for at least four weeks after discontinuation. Its literature search ran through March 2024.

Across included medicines, statistically significant regain relative to controls appeared at eight weeks and remained at 12 and 20 weeks; the GLP-1-related subgroup showed significant regain at 12 weeks. The studies differed by medicine, population, prior weight loss, ongoing lifestyle support, and follow-up, and the 12-week estimate had substantial heterogeneity. The review supports a short-term group-level regain signal, not a product ranking or individual prediction.

What current labels do — and do not — answer

Current DailyMed labels for Wegovy and Zepbound include product-specific indications to reduce excess body weight and maintain weight reduction long term in defined populations. Wegovy SPL version 19 was published June 30, 2026; Zepbound SPL version 38 was published May 6, 2026.

That regulatory language describes approved use of each exact product. It does not compare discontinuation strategies, predict post-treatment regain, or make the STEP 1 and SURMOUNT-4 populations interchangeable. Label language also should not be applied to compounded or otherwise unapproved versions.

Lean mass and support questions need a narrower claim

A 2026 systematic review of 20 randomized trials and 15,782 adults examined lean-mass changes during weight-loss interventions with incretin therapies or intensive lifestyle approaches. It did not establish post-discontinuation body-composition outcomes or an individualized protein or activity target.

The education-only takeaway is to ask a clinician or registered dietitian whether nutrition adequacy, strength or function, symptoms, and follow-up need attention in a reader's circumstances. The evidence reviewed here does not support a universal diet, protein, exercise, tapering, or maintenance protocol.

Evidence gaps to keep explicit

Evidence gap: the reviewed sources do not establish one best way to discontinue treatment, whether tapering changes regain, or which diet, exercise, behavioral, or monitoring approach prevents regain after GLP-1 therapy stops.

Evidence beyond one year after withdrawal is limited in the primary studies reviewed here. Evidence is also insufficient to generalize these results to people with diabetes, adolescents, pregnancy, older adults as a distinct group, prior bariatric surgery, every GLP-1-related product, or compounded and unapproved products.

• Which evidence applies to the exact product, indication, health history, and reason treatment may change?
• What follow-up measures and symptoms would a clinician want to review after an interruption or stop?
• Which questions belong with a clinician, registered dietitian, or other qualified professional rather than an online protocol?

Sources and further reading

These links are included to make the evidence trail visible. They are not sponsor links and do not replace product-specific medical advice.